机构投资者推动Novo Nordisk的股权;公司压倒收入,提高红利。 Institutional investors boost Novo Nordisk stakes; company beats earnings, raises dividend.

机构投资者增加了在Novo Nordisk A/S公司的股份,Cutter & CO 经纪公司将其持有量提高了2.9%。 Institutional investors have increased their stakes in Novo Nordisk A/S, with Cutter & CO Brokerage Inc. raising its holding by 2.9%. 该公司报告EPS为0.91美元,击打估计数为0.03美元,并宣布半年期增收红利为0.7874美元,收益为1.2%。 The company reported an EPS of $0.91, beating estimates by $0.03, and announced a boosted semi-annual dividend of $0.7874, a yield of 1.2%. 分析员将公司评为“机动买家”,平均目标价格为145.25美元。 Analysts rate the company as a "Moderate Buy" with an average target price of $145.25. Novo Nordisk的重点是糖尿病、肥胖症护理和罕见疾病。 Novo Nordisk focuses on diabetes, obesity care, and rare diseases.